BioCentury
ARTICLE | Clinical News

MDCO-216: Phase I data

November 24, 2014 8:00 AM UTC

A placebo-controlled Phase I trial in 24 healthy volunteers and 24 patients with documented coronary artery disease (CAD) showed that single doses of 5-40 mg/kg MDCO-216 were well tolerated with no se...